Solriamfetol · Sunosi
Small molecule
Also known as JZP-110
Evidence outlook
Approved: Narcolepsy
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Major Depressive Disorder · Phase 3 · investigational in the USAttention Deficit Hyperactivity Disorder · Phase 3 · investigational in the US
Also approved (2)
- Excessive daytime sleepiness in adults with narcolepsy and in adults with obstructive sleep apnea
- Improve wakefulness and reduce excessive daytime sleepiness in adults with narcolepsy (with or without cataplexy) or obstructive sleep apnoea
Development in Parkinson's Disease stopped for reasons the sponsor has not stated. Source
Company guidance: topline data expected 1H 2027 (NCT07484217; Axsome Therapeutics, 2 Nov 2026). “Placebo Solriamfetol (150 mg) Solriamfetol for the treatment of MDD with EDS symptoms Key eligibility criteria 18-65 years of age with diagnosis of MDD (DSM-5 criteria) Symptoms of excessive daytime sleepiness Double-blind phase Primary endpoint Time from randomization to relapse of depressive symptoms Solriamfetol (150 mg) CLARITY Phase 3 trial Open-label period Baseline 1:1 randomization (Patients achieving treatment response) 38 1:1 R Enrollment completion anticipated 1H 2027” Source ↗
Company guidance: topline data expected 2H 2027 (Axsome Therapeutics, 2 Nov 2026). “Solriamfetol for the treatment of shift work disorder Key eligibility criteria 18-65 years of age with diagnosis of SWD (ICSD-2 or ICSD-3) Primary endpoint Change from baseline in MWT Placebo Solriamfetol (150 mg) Screening (1-4 weeks) Double-blind phase (up to 12 weeks) Baseline 1:1 R N=450 Follow-up (1 week) SUSTAIN Phase 3 trial Topline results anticipated 2H 2027 MWT = Maintenance of Wakefulness Test 36” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02348593 NCT02348593 · Narcolepsy TONES 2 (Study 1 in the SUNOSI label) was a 12-week, randomized, double-blind, placebo-controlled Phase 3 trial in 239 adults with narcolepsy, testing solriamfetol 75, 150 and 300 mg. The coprimaries were the change in Maintenance of Wakefulness Test sleep latency and in Epworth Sleepiness Scale score. The 150 and 300 mg doses were significant on both (all p<0.0001), but the 75 mg dose was not significant on either. With two doses positive and one not, the result is mixed. Sources: the FDA label (SUNOSI) and Thorpy et al., Ann Neurol 2019. Registry: NCT02348593 | 3 | Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12; Change in ESS Score From Baseline to Week 12 2017-02 | Change from baseline to week 12 vs placebo: MWT +12.3 (300 mg) and +9.8 (150 mg) vs +2.1 minutes; ESS -6.4 and -5.4 vs -1.6 points (all p<0.0001). The 75 mg dose (MWT +4.74, ESS -3.8) was not statistically significant on either coprimary (Thorpy et al., Ann Neurol 2019; SUNOSI label). | Partial signal | link ↗ |
View 2 more trials
NCT02348632 NCT02348632 · Narcolepsy Study 4 in the SUNOSI label enrolled 638 adults with narcolepsy or obstructive sleep apnea who had completed an earlier solriamfetol trial and gave all of them the drug open-label. After about six months on a stable dose, 282 participants entered a 2-week randomized withdrawal, in which half continued solriamfetol and half switched to placebo. The single primary endpoint was the change in Epworth Sleepiness Scale score over that period. Sleepiness worsened much more after the switch to placebo (+5.3 vs +1.6 points; difference -3.7, 95% CI -4.8 to -2.7), so the primary endpoint was met. Sources: the FDA label (SUNOSI) and the CT.gov posted results. Registry: NCT02348632 | 3 | Change in Epworth Sleepiness Scale (ESS) Score (Start of randomized withdrawal phase to end of randomized withdrawal (2 weeks)) 2017-12 | Change in Epworth Sleepiness Scale score from the start to the end of the 2-week randomized-withdrawal period (positive = worse): +1.6 with continued solriamfetol (n=139) vs +5.3 after switch to placebo (n=141); difference -3.7 points (95% CI -4.8 to -2.7), significant after multiplicity adjustment (SUNOSI label Table 8; CT.gov posted results). | Partial signal | link ↗ |
OSA NCT02348619 · Obstructive Sleep Apnea Registry: NCT02348619 | 3 | Change in the Maintenance of Wakefulness Test (MWT) (Week 4 to Week 6); Change in the Epworth Sleepiness Scale (ESS) (Week 4 to Week 6) 2016-11 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (14)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Dopamine/norepinephrine transporter drugs
Dextromethorphan/bupropion, naltrexone/bupropion. Compare all 3 Dopamine/norepinephrine transporter drugs
2 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Major Depressive Disorder: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Solriamfetol (Sunosi): this drug | Phase 3 | Small molecule | Dopamine/norepinephrine transporter | Partial signal | NCT06360419: In the overall patient population the study did not demonstrate a statistically significant change on the Montgomery-Asberg Depression Rating Scale (MADRS) total score compared to placebo, the study's primary endpoint. Patients with MDD with severe excessive daytime sleepiness (n=51) and without severe EDS (n=295) were randomized to solriamfetol 300 mg or placebo. missed | |
| Aripiprazole (Abilify) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Brexpiprazole (Rexulti) | Approved | Small molecule | Dopamine D2/D3 and serotonin 5-HT1A receptor | Partial signal | NCT01360645: Change From Baseline (End of Phase A [Week 8]) to Week 14 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score for the Efficacy Sample. (Baseline and Week 14): Brexpiprazole 2 mg/Day + ADT -8.27 Units on a scale (Standard Error 0.61) vs Double-blind Placebo + ADT -5.15 Units on a scale (Standard Error 0.6) NCT01360632: Mean Change From the End of Phase A (Week 8 Visit) to Phase B (Week 14 Visit) in the Montgomery-Asberg Depression Rating Scale for the Efficacy Sample Set (Baseline and Week 14): Brexpiprazole (1mg) + ADT -7.65 Units on a scale (Standard Error 0.5) | Brexpiprazole (3mg) + ADT -7.98 Units on a scale (Standard Error 0.51) vs Placebo + ADT -6.45 Units on a scale (Standard Error 0.51) | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | Partial signal | NCT03738215: Total Score Change From Baseline to Week 6 in the MADRS (Montgomery-Åsberg Depression Rating Scale) (Baseline and Week 6): Cariprazine 1.5 mg/Day + ADT -14.1 score on a scale (Standard Error 0.7) | Cariprazine 3 mg/Day + ADT -13.1 score on a scale (Standard Error 0.7) vs Placebo + ADT -11.5 score on a scale (Standard Error 0.7) | |
| Dextromethorphan / Bupropion (Auvelity) | Approved | Small molecule | sigma-1/NMDA, Dopamine/norepinephrine transporter | Partial signal | NCT04019704: Change in MADRS Total Score From Baseline to Week 6 (6 weeks): AXS-05 15.91 score on a scale (Standard Error 0.921) vs Placebo 12.04 score on a scale (Standard Error 0.862) NCT02741791: Primary endpoint, MADRS total score change from baseline to Week 6: -11.6 with AXS-05 vs -9.4 with bupropion (active comparator); difference not statistically significant, p=0.117 missed | |
| Duloxetine (Cymbalta) | Approved | Small molecule | Serotonin/norepinephrine transporter, Serotonin and norepinephrine transporters (SERT/NET) | not yet graded | No reviewed efficacy summary in this indication | |
| Esketamine (Spravato) | Approved | Small molecule | NMDA receptor | Partial signal | NCT02418585: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 in the Double-blind Induction Phase- Mixed-Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine (Esk) Plus Oral Antidepressant (AD) -21.4 Units on a scale (Standard Deviation 12.32) vs Intranasal Placebo Plus Oral AD -17 Units on a scale (Standard Deviation 13.88) NCT02417064: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28 of Double- Blind Induction Phase- Mixed- Effects Model Using Repeated Measures (MMRM) Analysis (Baseline up to Day 28 of Double-blind Induction Phase): Intranasal Esketamine 56 mg Plus Oral Antidepressant -19 Units on a scale (Standard Deviation 13.86) | Intranasal Esketamine 84 mg Plus Oral AD -18.8 Units on a scale (Standard Deviation 14.12) vs Oral AD Plus Intranasal Placebo -14.8 Units on a scale (Standard Deviation 15.07) missed | |
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | Weak signal | NCT05061706: Montgomery-Asberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 units on a scale (Standard Error 0.56) | Placebo -10.2 units on a scale (Standard Error 0.54) NCT04985942: Montgomery-Åsberg Depression Rating Scale (Day 43): Lumateperone 42 mg -14.7 score on a scale (Standard Error 0.54) | Placebo -9.8 score on a scale (Standard Error 0.53) | |
| Naltrexone / Bupropion (Contrave) | Approved(overall) | Small molecule | Opioid receptor / dopamine (combination), Dopamine/norepinephrine transporter | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Quetiapine (Seroquel XR) | Approved | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Vortioxetine (Trintellix) | Approved | Small molecule | Serotonin transporter + multiple 5-HT receptors | Partial signal | NCT00596817: Relapse Within First 24 Weeks of the Double-blind Period Based on a MADRS Total Score >=22 or an Unsatisfactory Treatment Effect (Lack of Efficacy) as Judged by the Investigator (Within first 24 weeks of the double-blind period): Vortioxetine: 5 or 10 mg 13.2 percentage of patients who relapsed vs Placebo 26 percentage of patients who relapsed NCT02709655: Change From Baseline in Children Depression Rating Scale - Revised (CDRS-R) Total Score at Week 8 of Phase B (Baseline (Week 4 of Phase A), Week 8 of Phase B): Double-Blind: Vortioxetine 10 mg -19.2 units on a scale (Standard Error 1.37) | Double-Blind: Vortioxetine 20 mg -19.94 units on a scale (Standard Error 1.37) vs Double-Blind: Placebo -17.48 units on a scale (Standard Error 1.35) | Double-Blind: Fluoxetine 20 mg -20.78 units on a scale (Standard Error 1.6) missed | |
| Ammoxetine | Phase 3 | Small molecule | Serotonin/norepinephrine transporter | Partial signal | NCT06827431: Primary endpoint, week-8 MADRS change: significantly better than placebo (P<0.0001) and numerically better than sertraline (2026-07-27). | |
| Ansofaxine Hydrochloride | Phase 3 | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT04853407: MADRS total score change from baseline at Week 8: ansofaxine 80 mg -20.0, ansofaxine 160 mg -19.9, placebo -14.6 (p<0.0001). | |
| Azetukalner | Phase 3 | Small molecule | Kv7 potassium channel | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 3 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Deupsilocin | Phase 3 | Small molecule | 5-HT2A receptor | Partial signal | NCT05385783: Primary endpoint (3-week MADRS change vs placebo): -14.08 point difference after a single 12mg dose (p=0.0005, Cohen's d=2.151) | |
| KH607 | Phase 3 | Small molecule | GABA-A receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Lysergide Tartrate (LSD) (DT120) | Phase 3 | Small molecule | 5-HT2A receptor | Reliable signal | NCT06941844: Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. | |
| Milsaperidone (VHX-896) | Phase 3 | Small molecule | Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Osavampator | Phase 3 | Small molecule | AMPA receptor (positive allosteric modulator) | Partial signal | NCT05203341: MADRS total score change at Day 28 vs placebo (company topline): one dose -4.3 (p = 0.0159); the other dose -3.0 (p = 0.0873, not significant). Day 56: -7.5 (p = 0.0016) and -3.6 (p = 0.1082). | |
| Psilocybin (COMP360) | Phase 3 | Small molecule | 5-HT2A receptor | Reliable signal | NCT05711940: COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001. NCT05624268: Change in MADRS total score from baseline to Week 6 (COMP005 trial): COMP360 25 mg vs placebo, mean treatment difference -3.6 points (95% CI -5.7 to -1.5; p<0.001) | |
| Seltorexant | Phase 3 | Small molecule | Orexin-2 receptor (OX2R) | Partial signal | NCT04533529: Double Blind (DB) Treatment Phase: Change From Baseline to Day 43 in Montgomery- Asberg Depression Rating Scale (MADRS) Total Score- Estimand 1 (Baseline (Day 1), Day 43): DB Treatment Phase: Seltorexant 20 mg -12.9 Units on a scale (Standard Deviation 9.63) vs Double Blind (DB) Treatment Phase: Placebo -10.5 Units on a scale (Standard Deviation 10.26) NCT04513912: Response (>=50% MADRS improvement) at week 26: 57.4% seltorexant vs 53.4% quetiapine XR; did not reach statistical significance missed | |
| D-Cycloserine / Lurasidone (NRX-101) | Phase 2/3 | Small molecule | NMDA receptor (glycine site) + dopamine/5-HT receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Mitizodone Phosphate | Phase 2/3 | Small molecule | Serotonin transporter/5-HT receptor | Weak signal | No reviewed efficacy summary in this indication | |
| ACP-211 | Phase 2 | Small molecule | NMDA receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ALTO-100 | Phase 2 | Small molecule | First-in-class oral small molecule neural plasticity enhancer | Partial signal | NCT05117632: MADRS reduction at Week 6: 15.5 points (biomarker-defined group) vs 10.6 points (biomarker-negative group); clinical response (>=50% MADRS reduction): 61% vs 33% | |
| ALTO-203 | Phase 2 | Small molecule | Histamine H3 receptor (antagonist / inverse agonist) | Partial signal | No reviewed efficacy summary in this indication | |
| ALTO-300 | Phase 2 | Small molecule | Melatonergic (MT) receptors (agonist) + serotonin receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Arketamine (PRT042) | Phase 2 | Small molecule | NMDA receptor | not yet graded | No reviewed efficacy summary in this indication | |
| AV-101 | Phase 2 | Small molecule | NMDA receptor | Partial signal | NCT02484456: Model Adjusted Means for Hamilton Depression Rating Score (Post Dose Day 0): AV 101 (4-chlorokynurenine) 20.22 score on a scale (Standard Error 0.68) vs Placebo 20.56 score on a scale (Standard Error 0.51) missed | |
| BI 1569912 | Phase 2 | Small molecule | NMDA receptor | Partial signal | NCT06558344: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements at baseline, Day 8, Week 2, Week 4, and Week 6. Change from baseline values at Week 6 is reported.): 5 mg BI 1569912 -13.6 Units on a scale (95% CI -17.8 to -9.4) | 10 mg BI 1569912 -10.6 Units on a scale (95% CI -14.5 to -6.7) | 20 mg BI 1569912 -10 Units on a scale (95% CI -12.9 to -7.2) vs Placebo-matching BI 1569912 -10.3 Units on a scale (95% CI -13.1 to -7.5) missed NCT06280235: Change From Baseline in MADRS Total Score at Week 6 (MMRM included measurements from baseline and Day 8, Week 4, Week 6 after first drug administration. MMRM estimates of change from baseline to Week 6 in MADRS total score is reported.): 5 mg BI 1569912 -7.8 units on a scale (95% CI -11 to -4.6) | 10 mg BI 1569912 -11.9 units on a scale (95% CI -15 to -8.7) | 20 mg BI 1569912 -12.3 units on a scale (95% CI -14.6 to -10) vs Placebo -12 units on a scale (95% CI -14.2 to -9.7) missed | |
| Blixeprodil | Phase 2 | Small molecule | NMDA receptor | Weak signal | Featured results are safety only in this race | |
| BPL-003 (mebufotenin Benzoate) | Phase 2 | Small molecule | 5-HT2A receptor | Partial signal | NCT05870540: MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025). | |
| Bretisilocin | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cyclobenzaprine (Tonmya) | Phase 2 | Small molecule | 5-HT2A, α1-adrenergic, H1-histaminergic, and M1-muscarinic acetylcholine receptors (functional antagonism) | not yet graded | No reviewed efficacy summary in this indication | |
| DT-101 | Phase 2 | Small molecule | AMPA receptor (positive allosteric modulator) | not yet graded | No reviewed efficacy summary in this indication | |
| Elunetirom | Phase 2 | Small molecule | Thyroid hormone receptor-beta | not yet graded | No reviewed efficacy summary in this indication | |
| Emestedastat (Xanamem) | Phase 2 | Small molecule | 11-beta-HSD1 | Partial signal | NCT05657691: Primary endpoint (Attention Composite cognitive score, week 6) missed: least squares mean change 0.32 (emestedastat) vs 0.46 (placebo), difference -0.13 (95% CI -0.32 to 0.06), p=0.17 favouring placebo. (MADRS depression score was only a secondary endpoint, borderline at p=0.05.) missed | |
| Esketamine (CLE-100) | Phase 2 | Small molecule | NMDA receptor | Partial signal | NCT06340958: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) missed NCT04103892: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Part B - CLE-100 (Oral Esketamine) -10.72 units on a scale (Standard Error 1.13) vs Part B - Placebo -9.46 units on a scale (Standard Error 1.31) missed | |
| Evifacotrep | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Forvisirvat | Phase 2 | Small molecule | SIRT6 | Partial signal | NCT04479852: Change From Baseline to Week 4 in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Baseline to Week 4): SP-624 -12.6 Score on a scale (Standard Error 0.83) vs Placebo -10.8 Score on a scale (Standard Error 0.84) missed | |
| GlyphAllo (allopregnanolone Prodrug) (SPT-300) | Phase 2 | Small molecule | GABA-A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| GW117 | Phase 2 | Small molecule | Melatonin MT1/MT2 receptor + 5-HT2C receptor | Partial signal | NCT06796868: Change in HAMD-17 total score from baseline at Week 8 (FAS, n=276): placebo -13.46, GW117 20mg -14.62, 40mg -14.34, 60mg -13.75; numerically greater reductions with GW117 but not statistically significant vs placebo. missed | |
| HS-10353 | Phase 2 | Small molecule | GABA-A receptor | Weak signal | NCT05195203: Phase 1 SAD (healthy, 2-55mg)/MAD (MDD patients, 15-65mg/day) trial: safe and well tolerated, no dose-adjusting AEs; exploratory HAM-D17 signal at 50mg dose: -4.7 vs placebo (95% CI -8.9 to -0.5), not significant at other doses | |
| Hypidone (YL-0919) | Phase 2 | Small molecule | Serotonin transporter/5-HT1A receptor/sigma-1 receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Icalcaprant | Phase 2 | Small molecule | Kappa-opioid receptor (inhibitor) | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-89495120 | Phase 2 | Small molecule | Muscarinic M1 receptor (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Liafensine | Phase 2 | Small molecule | Serotonin/norepinephrine/dopamine transporter | Reliable signal | NCT05113771: Change in Montgomery Åsberg Depression Rating Scale (MADRS) Total Score From Baseline to Day 42, in DGM4-positive Patients (Baseline to Day 42): Liafensine 1mg -15.4 Units on a Scale (Standard Error 1.25) | Liafensine 2mg -15.5 Units on a Scale (Standard Error 1.3) vs Placebo -11 Units on a Scale (Standard Error 1.31) NCT01369095: In the CN162-007 study, the adjusted mean (SE) change in MADRS total score was -7.3 (0.830) and -6.6 (0.842) for BMS-820836 of 1 and 2 mg, respectively, and -6.9 (0.602) for the continuation group (P = 0.910). missed | |
| LV232 | Phase 2 | Small molecule | Serotonin transporter + 5-HT3 receptor | Weak signal | No reviewed efficacy summary in this indication | |
| Mebufotenin (5-MeO-DMT) (GH001) | Phase 2 | Small molecule | 5-HT2A receptor | Partial signal | NCT05800860: Placebo-adjusted MADRS reduction from baseline at Day 8: -15.5 points (LS mean difference -15.5, effect size -2.0, P<0.0001) | |
| Nelivaptan | Phase 2 | Small molecule | Vasopressin V1B receptor | Partial signal | NCT00358631: Change from baseline to Day 56 in HAM-D-17 total score (LS mean, SE): nelivaptan 250mg BID -10.7 (0.94) vs placebo -7.68 (0.95); difference from placebo -3.03 (95% CI -5.66 to -0.39; p=0.0244). 100mg BID nelivaptan and escitalopram 10mg QD arms did not separate from placebo. | |
| NH102 | Phase 2 | Small molecule | Serotonin/norepinephrine/dopamine transporter + 5-HT2A receptor | Partial signal | No reviewed efficacy summary in this indication | |
| PDC-1421 | Phase 2 | Botanical | Polygalae radix extract (active components: tenuifolin, polygalasaponins, etc.) | Partial signal | NCT02395978: Change of Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Baseline to Week 6 Compared to Placebo for Part II. (From Baseline to Week 6): Part II: 2 PDC-1421 Capsule — ITT population: -13.19 score on a scale (Standard Deviation 9.68); PP population: -13.4 score on a scale (Standard Deviation 9.7) | Part II: 1 PDC-1421 Capsule Plus 1 Placebo — ITT population: -9.21 score on a scale (Standard Deviation 8.32); PP population: -10.4 score on a scale (Standard Deviation 5.18) vs Part II: 2 Placebo — ITT population: -9.2 score on a scale (Standard Deviation 7.98); PP population: -8.6 score on a scale (Standard Deviation 7.61) | |
| Pramipexole / Ondansetron (ALTO-207) | Phase 2 | Small molecule | Dopamine D3-preferring D3/D2 receptors (agonist) + 5-HT3 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Ropanicant | Phase 2 | Small molecule | Alpha4beta2 nicotinic acetylcholine receptor | Partial signal | NCT06836063: MADRS total score change from baseline vs placebo at Week 6: mean difference -3.572 (FAS, p=0.038), -4.067 (PP set, p=0.023) -- primary endpoint met. NCT03155503: Safe and well tolerated in healthy subjects at single doses up to 60 mg and multiple doses up to 45 mg once daily. Pharmacokinetics were nonlinear with accumulation on multiple dosing: 1.5- to 2.5-fold higher maximum concentration and 1.6- to 4.0-fold higher AUC from 0 to 24 h on day 14 compared with day 1. | |
| SPN-820 | Phase 2 | Small molecule | mTORC1 | Partial signal | NCT05066672: Change From Baseline to Week 4 in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score. (Baseline to Week 4): NV-5138 (800 or 1600 mg) -12.2 units on a scale (Standard Deviation 9.66) | Placebo -11.6 units on a scale (Standard Deviation 10.64) missed | |
| SPN-821 | Phase 2 | Small molecule | mTORC1 (mammalian target of rapamycin complex 1) (activator) | not yet graded | No reviewed efficacy summary in this indication | |
| VLS-01 | Phase 2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Zelquistinel | Phase 2 | Small molecule | NMDA receptor | Partial signal | NCT03726658: Part A: Change in MADRS Score at 1 Day the Initial Dose of AGN-241751 Reported as Change From Baseline in Treated Group Compared With Change From Baseline in Placebo Group (Baseline (Day1) to Day 2): AGN-241751 3mg Daily -9.4 score on a scale (Standard Error 1.57) | AGN-241751 10mg Daily -6.7 score on a scale (Standard Error 1.58) | AGN-241751 25mg Daily -9.5 score on a scale (Standard Error 1.57) vs Placebo Daily -9.3 score on a scale (Standard Error 1.61) missed | |
| ELE-101 | Phase 1/2 | Small molecule | 5-HT2A receptor | not yet graded | No reviewed efficacy summary in this indication | |
| ALA-3000 | Phase 1 | Small molecule | NMDA receptor | Partial signal | Featured results are safety only in this race | |
| Apimostinel | Phase 1 | Small molecule | NMDAR agonist/modulator | Weak signal | Featured results are safety only in this race | |
| ENX-104 | Phase 1 | Small molecule | Dopamine D2/D3 receptor (antagonist) | Weak signal | No reviewed efficacy summary in this indication |
Large race: only the 62 furthest-along competitors are listed; 8 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Compare side by side
Upcoming events
(8 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Sunosi (Solriamfetol) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (3)
December 2026 (3)
What to watch
What to watch
What to watch
2027 (2)
2028 (3)
June 2028 (2)
December 2028 (1)
Company guidance: topline data expected 1H 2027 (Axsome Therapeutics, 2 Nov 2026). “Placebo Solriamfetol (150 mg) Solriamfetol for the treatment of MDD with EDS symptoms Key eligibility criteria 18-65 years of age with diagnosis of MDD (DSM-5 criteria) Symptoms of excessive daytime sleepiness Double-blind phase Primary endpoint Time from randomization to relapse of depressive symptoms Solriamfetol (150 mg) CLARITY Phase 3 trial Open-label period Baseline 1:1 randomization (Patients achieving treatment response) 38 1:1 R Enrollment completion anticipated 1H 2027” Source ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent